If Joe is out of other options, I think he has to move
If Joe is out of other options, I think he has to move forward. But maybe he can sell the higher valuation off of this $500MM base. Maybe there are people who see this as a $1B+ company that will pay enough to come out of the gate with 200-300MM shares.
Whatever the case, we have a jumping off point, and we can move forward. Nothing good is going to come by waiting much longer.
Also, if Joe is keeping 60%, it tempers the initial hit of the valuation quite a bit. If Joe can see a path to NGIO trading at $20, $50, or more /sh or more (with this lowered share count) a year from now, he still has 90MM shares and a hell of an asset on the books.
1
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Top 5 Most Recently Viewed Articles
Introducing a Unique Investment Opportunity Kay Properties & Investments has just added an exciting asset to its online 1031 Exchange Delaware Statutory Trust (DST) marketplace. This offering, known as "The Peanut Factory Lofts," is a revitalized multifamily property that stands out due to its innovative design and strategic location. About the Peanut Factory Lofts The...
Continue Reading
TAQA North and ISN Collaborate for Enhanced Safety TAQA North Ltd has teamed up with ISN to boost contractor safety standards and compliance processes. ISN is known for its expertise in contractor management, helping organizations optimize their operational efficiency. This partnership is a significant milestone for TAQA North, a key entity in Canada's oil and gas...
Continue Reading
Financial Results and Clinical Developments Compass Therapeutics, Inc. (Nasdaq: CMPX), a dynamic biopharmaceutical company focused on oncology, has recently unveiled its financial results for the third quarter of 2025, highlighting significant progress in their clinical pipeline. The company continues to make strides in developing innovative antibody-based therapies aimed...
Continue Reading
Magna International Inc. (TSX: MG) (NYSE: MGA) stirred up chatter among traders with their impending Q3 2024 results call scheduled for November 1, 2024. Now, if you’ve been in the trenches long enough, you know these calls can be a wild ride—especially when investors are itching to uncover how a company’s really performing behind the PR curtain. What to Expect from...
Continue Reading
TransUnion to Present at the Barclays Global Financial Conference TransUnion (NYSE: TRU) is making headlines as Chris Cartwright, the President and CEO of the company, prepares to showcase the organization's mission and vision at the Barclays Global Financial Services Conference. This prominent gathering is set for September, providing an excellent platform for industry...
Continue Reading